A Bellevue-based biotech firm, Viome Life Sciences, continues its upward trajectory, securing an additional $19.5 million in its Series C financing, bringing the total for this round to $86.5 million. This recent closure of the funding round comes on the heels of its initial $67 million raise in October, and the company is now expanding its physical presence in Bothell.
Viome, already operating with 22,000 square feet of lab space in Bothell, has revealed plans to add approximately 45,000 square feet more, with an aspiration to achieve this expansion potentially by year-end, according to a report in the Puget Sound Business Journal.
Naveen Jain, the founder and CEO of Viome, outlined the company’s strategy in the report, stating, “The new funding is to obviously continue to grow our consumer business and also facilitate the growth of the professional side of our business. We’ll also be looking at many other new products.”
Founded in 2016, Viome has carved a niche with its innovative at-home gut and full-body health tests. These diagnostic tools, according to the company’s claims, offer insights into the underlying causes for diverse health challenges ranging from heart and digestive issues to mood fluctuations and immune system concerns. Pivoting on the results of these tests, Viome dispatches personalized supplements in various forms, like pills and powders, designed to augment users’ well-being.
Beyond its core products, the firm’s catalog includes at-home oral health tests and lozenges. Viome’s distribution strategy is twofold: direct-to-consumer and through medical practitioners. Cumulatively, the company’s funding has accrued $175 million, a sum which also factors in a $54 million round from November 2021.
The company currently employs a workforce of approximately 135, with the vast majority, around 125, stationed in the Seattle region, Jain highlighted. While future hiring plans remain unspecified, the firm’s footprint extends beyond Bothell. Viome’s headquarters in Bellevue spans 9,200 square feet, supplemented by satellite offices in New York City and Dallas.
This latest funding round saw involvement from investors like Khosla Ventures, Bold Capital, and WRG Ventures.
